Epanova® and hypertriglyceridemia: Pharmacological mechanisms and clinical efficacy

Yu Kataoka, Kiyoko Uno, Rishi Puri, Stephen J. Nicholls

Research output: Contribution to journalArticleResearchpeer-review

11 Citations (Scopus)

Abstract

While LDL-cholesterol lowering has become the cornerstone of cardiovascular risk reduction strategies, considerable interest in additional targeting of hypertriglyceridemia continues. While ω-3 fatty acids are commonly used in clinical practice for triglyceride lowering, no large-scale clinical trial evaluating their impact on clinical events has been performed. As a result, there remains a lack of consensus with regards to their optimal clinical use. Epanova® (Omthera Pharmaceuticals Inc., NJ, USA) is a novel ω-3 free fatty acid formulation, developed to maximize eicosapentenoic acid and docosahexenoic acid bioavailability with low-fat diets, suggesting a potential therapeutic advantage compared with ω-3-acid ethyl esters in the treatment of patients with hypertriglyceridemia. Additional human studies are needed to define more clearly the cellular and molecular basis for the triglyceride-lowering effects of Epanova and this drug's favorable cardiovascular effects, particularly in patients with hypertriglyceridemia.

Original languageEnglish
Pages (from-to)177-186
Number of pages10
JournalFuture Cardiology
Volume9
Issue number2
DOIs
Publication statusPublished - 1 Mar 2013
Externally publishedYes

Keywords

  • ω-3 free fatty acid
  • ω-3-acid ethyl esters
  • docosahexenoic acid
  • eicosapentenoic acid
  • Epanova®
  • hypertriglyceridemia

Cite this